Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 4/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30041839 | 0.82 | CYP2A6 (0.43) | NPC1RAB9ATP53TSHRNFKB1 | |
| SCHEMBL527009 | 0.82 | CYP2A6 (0.43) | NPC1RAB9ATP53TSHRNFKB1 | |
| SCHEMBL12130901 | 0.81 | RAB9A (0.42) | NPC1RAB9ATP53TSHRNFKB1 | |
| SCHEMBL4867807 | 0.78 | AHR (0.42) | TDO2SMN1; SMN2MAOB | |
| SCHEMBL1349546 | 0.78 | KDM4E (0.46) | NPC1RAB9ATSHRSMN1; SMN2IDO1 | |
| SCHEMBL3648562 | 0.74 | GSTP1 (0.48) | TSHRSMN1; SMN2DHFRADORA2AADORA1 | |
| SCHEMBL29414736 | 0.74 | GSTP1 (0.48) | TSHRSMN1; SMN2DHFRADORA2AADORA1 | |
| SCHEMBL2646929 | 0.72 | CASP1 (0.41) | NPC1RAB9ATP53SMN1; SMN2NOTUM | |
| SCHEMBL30453161 | 0.72 | CASP1 (0.41) | NPC1RAB9ATP53SMN1; SMN2NOTUM | |
| SCHEMBL9862849 | 0.72 | NPC1 (0.50) | TDO2NPC1RAB9ATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | TDO2 3885/4885NPC1 4017/4885RAB9A 1144/4885 |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | TDO2 3750/4885NPC1 4202/4885RAB9A 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.